Aβ42 promotes the aggregation of α‐synuclein splice isoforms via heterogeneous nucleation

Alexander Röntgen, Zenon Toprakcioglu, Michele VendruscoloFEBS 2025 · DOI

TL;DR

This study reveals that amyloid-beta (Aβ42), a key player in Alzheimer's disease, acts as a potent "seed" to accelerate the aggregation of alpha-synuclein (αSyn) splice isoforms, which are implicated in Parkinson's disease. This discovery provides a unified mechanism for how these two proteins co-aggregate, offering new therapeutic targets for neurodegenerative diseases.

What Problem Does This Paper Address?

Neurodegenerative diseases like Alzheimer's (AD) and Parkinson's (PD) are characterized by the misfolding and aggregation of specific proteins: amyloid-beta (Aβ) in AD and alpha-synuclein (αSyn) in PD. Increasingly, evidence points to these diseases co-occurring and influencing each other at a molecular level. Specifically, Aβ42, the more aggregation-prone form of Aβ, and various splice isoforms of αSyn (which arise from alternative splicing of the SNCA gene) are found together in affected brains. However, the precise molecular mechanisms governing this co-aggregation have been unclear, with conflicting reports on whether Aβ promotes or inhibits αSyn aggregation, and vice versa. This paper aims to systematically investigate how Aβ42 interacts with different αSyn splice isoforms to drive their aggregation, seeking to establish a unified mechanistic understanding.

Methods

The researchers employed a combination of biophysical and kinetic techniques:

  • Aggregation Assays (Thioflavin T - ThT fluorescence): This is a standard method to monitor amyloid formation. Proteins are incubated in the presence of ThT, a dye that fluoresces brightly when bound to amyloid fibrils. The increase in fluorescence over time indicates the rate and extent of aggregation.
  • Kinetic Analysis (AmyloFit 2.0): This computational platform was used to analyze the ThT fluorescence data, allowing the determination of kinetic rate constants and fitting the aggregation process to specific models.
  • SDS-PAGE: This technique separates proteins by size and was used to identify the specific protein species (Aβ42 or αSyn isoforms) present in aggregated (pellet) and soluble (supernatant) fractions at different time points. This helped to track the progression of aggregation for each protein.
  • Transmission Electron Microscopy (TEM): This high-resolution imaging technique was used to visualize the morphology of the formed amyloid aggregates, allowing researchers to compare the structures formed by different αSyn isoforms and under various conditions.

Datasets

Not discussed in the paper. The study relies on in vitro experiments using purified recombinant proteins.

Key Insights and Ideas

  • Aβ42 as a "Seed" for αSyn Aggregation: The most striking finding is that Aβ42, after forming its own initial fibrillar assemblies, acts as a potent "heterogeneous nucleation surface" for the aggregation of αSyn isoforms. This means pre-formed Aβ42 fibrils are much more effective at initiating αSyn aggregation than Aβ42 monomers.
  • Two-Step Process: The co-aggregation follows a distinct two-step process: first, Aβ42 aggregates into fibrils, and then these Aβ42 fibrils catalyze the aggregation of αSyn.
  • Splice Isoform Differences: The aggregation propensity of αSyn isoforms varies significantly. Isoforms lacking exon 5 (αSyn-112 and αSyn-98), which are more negatively charged, aggregate more readily and are more strongly promoted by Aβ42 compared to isoforms containing exon 5 (αSyn-140 and αSyn-126).
  • Low Aβ42 Concentrations Matter: Crucially, even very low, physiologically relevant concentrations of Aβ42 (down to nanomolar) were sufficient to promote αSyn aggregation, highlighting the significant impact of Aβ in neurodegenerative contexts.
  • αSyn Isoforms Don't Seed Aβ42: In a reciprocal experiment, pre-formed αSyn aggregates did not significantly accelerate Aβ42 aggregation, reinforcing the idea that Aβ42 initiates the co-aggregation cascade.
  • Morphological Consistency: Despite kinetic differences, the overall morphology of the amyloid fibrils formed by the αSyn isoforms in the presence of Aβ42 seeds resembled previously observed structures, suggesting that the underlying fibril formation mechanism is conserved.

Key Results

  • Accelerated αSyn Aggregation: The presence of Aβ42 monomers significantly accelerated the aggregation of αSyn-112 and αSyn-98 isoforms, reducing their half-times (t1/2) from over 240 hours to around 215 hours and 167 hours, respectively, with higher Aβ42 concentrations.
  • Pre-formed Aβ42 Seeds are More Potent: Pre-formed Aβ42 seeds reduced the aggregation half-times of αSyn-112 and αSyn-98 by approximately 40% compared to using Aβ42 monomers.
  • Aβ42 Promotes Aggregation of All Isoforms: Even the least aggregation-prone isoform, αSyn-140, showed aggregation when incubated with Aβ42 seeds, albeit on a longer timescale.
  • Low Aβ42 Concentrations Effective: Aggregation of αSyn isoforms was promoted by Aβ42 concentrations as low as 0.1 µM.
  • αSyn-112 Accelerates αSyn-140: Adding even small amounts (1-10%) of the αSyn-112 isoform to αSyn-140 in the presence of Aβ42 seeds significantly accelerated αSyn-140 aggregation.
  • No Aβ42 Acceleration by αSyn Aggregates: Incubation of Aβ42 monomers with pre-formed αSyn aggregates did not lead to accelerated Aβ42 aggregation.

Limitations and Future Work

  • In Vitro System: The study was conducted in vitro using purified proteins. While this provides a controlled environment to dissect molecular mechanisms, it doesn't fully replicate the complex cellular and in vivo environment of the brain. Future work could explore these interactions in cellular models and animal models of neurodegeneration.
  • Focus on Aβ42: The study primarily focused on Aβ42. While Aβ40 was briefly tested, a more comprehensive understanding of how different Aβ variants (including oligomers) interact with αSyn isoforms would be valuable.
  • Therapeutic Implications: The authors suggest that targeting these co-aggregation pathways could lead to novel therapeutic interventions. Future research could focus on developing specific inhibitors or modulators of this Aβ-αSyn interaction.
  • Role of Other Factors: The paper acknowledges that other factors (lipids, metal ions, etc.) can influence protein aggregation. Further investigation into how these factors modulate the Aβ-αSyn co-aggregation process would be beneficial.
  • Clinical Relevance of Splice Isoforms: While the study highlights the differential aggregation propensities of αSyn splice isoforms, further research is needed to fully elucidate their specific roles and clinical relevance in various neurodegenerative conditions.

Summary updated

Abstract

Increasing evidence suggests that amyloid-β (Aβ) and α-synuclein (αSyn) co-aggregate in Alzheimer's disease (AD) and Parkinson's disease (PD), an in other neurodegenerative disorders. We investigated how Aβ42 - the predominant Aβ form in AD - co-aggregates with four αSyn splice isoforms (αSyn-140, αSyn-126, αSyn-112 and αSyn-98) implicated in PD, finding evidence of a two-step process. Aβ42 first aggregated into fibrillar assemblies, which then acted as potent nucleation surfaces for initiating the aggregation of αSyn isoforms. Furthermore, pre-formed Aβ42 seeds promoted αSyn aggregation more strongly than in situ Aβ42 aggregates. Our results reveal a unified Aβ-αSyn co-aggregation mechanism, where Aβ aggregation and αSyn splicing synergistically drive co-deposition. These findings could help develop therapeutic tools to target key steps in disease-related co-aggregation pathways. Impact statement By demonstrating that Aβ42 fibril seeds serve as potent heterogeneous nucleation surfaces for four common α-synuclein splice isoforms, this study mechanistically links protein aggregation in Alzheimer's and Parkinson's diseases. Kinetic analysis identifies early cross-seeding events, suggesting intervention points to delay mixed amyloid pathologies in neurodegeneration.
BibTeX
@inproceedings{rontgen2025promotes,
  author = {Alexander Röntgen and Zenon Toprakcioglu and Michele Vendruscolo},
  title = {{Aβ42 promotes the aggregation of α‐synuclein splice isoforms <i>via</i> heterogeneous nucleation}},
  booktitle = {FEBS},
  year = {2025},
  doi = {10.1002/1873-3468.70118},
}
Figure